Kaida BioPharma Announces Formation of Scientific Advisory Board to Support Development of KAD101 for Ovarian Cancer Company appoints Anil K. Sood, MD, as inaugural member Company continues to advance lead program, KAD101 for the treatment of ovarian cancer rapidly advancing towards Phase 1 study, targeted for 2025...

Kaida BioPharma to Present at BioSparkVA Pitch Event FORT LAUDERDALE, FL, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Kaida BioPharma (“Kaida” or the “Company”), an early-stage pharma company dedicated to advancing ovarian cancer treatment through innovative...

Kaida BioPharma Launches Social Media Channels Company dedicated to providing a new hope for patients with treatment-resistant gynecological cancers Lead program, KAD101 for the treatment of ovarian cancer rapidly advancing towards Phase 1...

Kaida BioPharma to Present at the Virtual Investor Pitch Conference Live webcast on Monday, June 17th at 9:00 AM ET FORT LAUDERDALE, FL, June 17, 2024 (GLOBE NEWSWIRE) -- Kaida BioPharma (“Kaida” or the “Company”), an early-stage pharma company dedicated to...